AR and cancer: Upon using a novel AR antagonist as a warhead for AR, we prepared novel PROTACs by conjugating the antagonist to thalidomide, a representative E3 ligase recruiter known as the ligands of cereblon (CRBN) that forms an E3 ubiquitin ligase complex with Cullin-4A (CUL4A) and other compartments, through biologically compatible linking and biologically evaluated them as AR degraders in AR-positive cancer cells (Figure 2).